Alpha 5 beta 1 and its ability to regulate the cell survival pathway
View Patent ↗The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin α5β 1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy.
1. A method for disrupting survival signaling from a bone marrow microenvironment to single breast cancer cells or breast cancer cell micrometastases in a mammal with breast cancer, said method comprising administering to said mammal with breast cancer as adjuvant therapy an agent effective in blocking the interaction of an integrin with an extracellular matrix protein of the bone marrow microenvironment or that downregulates expression of said integrin, wherein the integrin is alpha 5 beta 1 and the extracellular matrix protein is fibronectin, and wherein the method results in sensitizing single breast cancer cells or breast cancer cell micrometastases to chemotherapy, biological therapies or radiation therapy of micrometastases in said mammal with breast cancer.
2. The method of claim 1 , wherein the agent is selected from the group consisting of an antibody specific for an integrin, a blocking peptide, and a modified peptide effective to disrupt interaction of the integrin with the extracellular matrix.
3. The method of claim 1 , wherein the method comprises blocking survival signaling initiated by ligation of alpha 5 beta 1 integrins by microenvironment proteins.
4. A method of inhibiting cellular proliferation or inducing cell death or cellular differentiation of single breast cancer cells or breast cancer cell micrometastases in a mammal with breast cancer or for treating a single breast cancer cell or breast cancer micrometastases in a mammal with breast cancer comprising administering to the mammal with breast cancer as adjuvant therapy an agent capable of downregulating expression of an integrin or blocking the binding of an integrin to an extracellular matrix protein of the bone marrow microenvironment, wherein the integrin is alpha 5 beta 1 and the extracellular matrix protein is fibronectin, and wherein the method results in inhibiting cellular proliferation or inducing cell death or cellular differentiation of the single breast cancer cell or breast cancer cell micrometastases or in treating the single breast cancer cell or breast cancer cell micrometastases in the mammal with breast cancer.
5. The method of claim 4 , comprising administering an antibody effective to block integrin alpha 5 beta 1 or a peptide effective to block fibronectin or a modified peptide effective to block fibronectin, or any combinations thereof, wherein the antibody or peptide is administered prior to or concurrent with a chemotherapeutic agent or radiation therapy.
6. The method of claim 4 , wherein the method results in sensitizing to, or potentiating chemotherapy or radiation therapy in mammals undergoing treatment for breast cancer.
7. The method of claim 1 , wherein the mammal with breast cancer is a human.
8. The method of claim 4 , wherein the mammal with breast cancer is a human.